NewsRoom Articles - Page 135 of 218

ThursdayDec 09, 2021 9:30 am

Data Analytics Show Decline in Cancer Screening in 2020

Most patients put off going to the doctor or skipped undergoing checkups because of the coronavirus pandemic last year. Despite infection cases dropping and vaccine rollout, data analytics still show a considerable drop in CT imaging for cancer. Researchers from Harvard Medical School and Massachusetts General Hospital conducted an analysis of CT exams for cancer that were conducted last year, both during the precoronavirus phase and the peak coronavirus phase, as well as in the post-coronavirus peak phase. The researchers studied the care delivered to patients via imaging as well as the CT volume, finding that during the disease’s peak,…

WednesdayDec 08, 2021 9:30 am

Virtual Care: How Small Businesses Can Use It to Save Time, Money

Virtual healthcare has become the new normal since the coronavirus pandemic began last year, with McKinsey & Company finding that the popularity of virtual primary care increased substantially in April 2020. Despite the potential to improve healthcare plans and reach more people, there still exist considerable barriers to the extensive adoption of virtual care. These include discomfort toward technology among individuals, especially older people, and the perception that the technology used is not secure. For the use of telehealth to continue growing, these barriers need to be addressed. A separate survey also found that virtual care is convenient and can…

TuesdayDec 07, 2021 11:13 am

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Finishing Up Significant 2021 Calendar Year

2021 marked Mydecine’s patent application for its MYCO-003 drug candidate It also marked notable clinical trials on various aspects, including smoking cessation Mydecine also got into a 5-year research agreement with JHU for clinical research on the use of psychedelics for therapeutics These milestones have laid down the groundwork, not just for Q3 of the 2021 financial year but also for the company’s growth in the 2022 calendar year Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), since its inception in 2020, has been aiming to transform the treatment of mental health disorders and addiction through biotechnology. The company…

TuesdayDec 07, 2021 11:00 am

Study Finds That Distance from Healthcare Facility May Impact Cancer Survival

A new study has found that the rate of survival for young individuals diagnosed with central nervous system (“CNS”) tumors is higher the farther they live from healthcare facilities. Associate professor at the Brown School at Washington University Kimberly Johnson reported that one of the possible causes for this was that patients who suffered from noncentral nervous system cancers likely lived further away from healthcare facilities, which increased the likelihood that they were diagnosed when their tumors were more difficult to treat and in advanced stages. In addition, patients with CNS tumors may have to travel farther for care in…

TuesdayDec 07, 2021 9:00 am

Nemaura Medical Inc. (NASDAQ: NMRD) Helping Diabetic Individuals Safeguard Themselves From COVID-19

1 in 8 adults are forecast to suffer from diabetes by 2024, with over 1 in 10 deaths in 2021 a direct result of the disease As many as 40% of Covid-19 related fatalities in the US also suffered from diabetes at the time of their passing Nemaura Medical is a medical technology company focused on developing non-invasive wearable diagnostic devices In addition to sugarBEAT, its flagship device, the company also recently announced the launch of MiBoKo, a combined application and non-invasive glucose sensor designed to help users track their metabolic scores By 2024, the International Diabetes Federation (“IDF”) predicts…

TuesdayDec 07, 2021 9:00 am

RYAH Group Inc. (CSE: RYAH) to Deliver Solutions for Clinicians Examining Cannabis Efficacy in Cancer Treatment

Multiple ongoing studies are researching the relationship between medical cannabis and cancer treatment The viability of clinical studies within the sector is hampered by lack of exact measurement of a patient’s intake RYAH Group intends to resolve this issue with the launch of it’s proprietary RYAH Smart Dry Herb Inhaler The company successfully delivered on its first Inhaler order in May 2021, and announced that they had received a follow-on order in November 2021 In 1980, The United States National Cancer Institute (“NCI”) began experimental distribution of a novel drug called Marinol, an oral form of THC (the primary active…

MondayDec 06, 2021 10:51 am

FDA green lights Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Psychedelic Drug Trial for Treating Fibromyalgia, After Completing IND Process

Pharmaceutical company Tryp Therapeutics is advancing research into the ability to treat unmet medical needs by using synthetic psychedelic drug candidates generally regarded as illegal and of no practical value under federal drug standards The company is demonstrating its faith in the potential of psychedelic medicine by advancing its proprietary TRP-8802 psilocybin candidate toward Phase 2a drug trials through the FDA’s Investigational New Drug process The FDA has notified the company that its review of the IND for using TRP-8802 to treat fibromyalgia is complete and a trial planned in conjunction with the University of Michigan may proceed to patient…

MondayDec 06, 2021 9:30 am

Missed Eating Disorder Diagnoses in Men Are on the Rise

Eating disorders are severe mental and physical illnesses that encompass damaging relationships with body image, exercise, eating and food. Research has found that behaviors that are linked to eating disorders, such as fasting for weight loss, purging and binge eating, are almost as common in men as they are in women. Figures from the National Eating Disorders Association also show that every one in three individuals suffering from an eating disorder is male. A study that was recently published in the “American Journal of Men’s Health” has found that eating disorder prevalence in men has been increasing, with data showing…

FridayDec 03, 2021 9:30 am

Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) Announces Research and Technology Progress, Offers Corporate Update

Investment banking firm The Maxim Group reiterates ‘buy’ rating on MCURF following the company’s updates on pivotal research and technology, including The Desire Project, manufacturing of synthetic ibogaine, and the iSTRYM platform MINDCURE is focused on developing psychedelic compounds to scale science-backed and evidentiary-based mental health therapy worldwide In July, MINDCURE filed for patents on two routes of full chemical synthesis, which initiated the production of Good Laboratory Practice (“GLP”) ibogaine, which will lead to the production of Good Manufacturing Practice (“GMP”) ibogaine to scale and manufacture a global supply of its synthetic ibogaine In addition to this pre-clinical trial,…

FridayDec 03, 2021 9:30 am

Baby Teeth Could Help Reveal Mental Illness Risk in Children

A new study has found that the growth lines in baby teeth may be used to identify children who are at risk for mental health conditions such as depression later in life. The study, which was conducted by researchers at the Massachusetts General Hospital, published its findings in JAMA Network Open. Researchers believe that their discovery could assist in the development of a tool that can identify children who have been exposed to adversity early in their lives. Early-life adversity is a risk factor for psychological issues. Erin C. Dunn, a social and psychiatric epidemiologist who studies the impact of…